Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Fermenta Biotech has informed that US FDA has issued an Establishment Inspection Report (EIR) for the Company’s manufacturing facility situated at Dahej, Gujarat, India with no observations as to any significant objectionable conditions, and the inspection has been successfully ‘closed’ by the US FDA.
The above information is a part of company’s filings submitted to BSE.